Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Cyclophosphamide, Bortezomib and Abatacept after Donor Stem Cell Transplant for the Prevention of Graft-versus-Host-Disease in Patients with Blood Cancers

Trial Status: complete

This phase I/II trial tests the safety, side effects, and best dose of abatacept when given together with cyclophosphamide and bortezomib, and tests whether these drugs work after a donor stem cell transplant in preventing graft-versus-host disease (GvHD) in patients with blood cancers. GvHD is a common complication after an allogeneic transplant. Cyclophosphamide has been widely studied for the prevention of GvHD. Cyclophosphamide inhibits fast dividing cells, specifically T cells, that are involved in the development of GvHD. Abatacept has been shown to block the pathway of T cell activation and multiplication. T cells play a key role in the development of GvHD and why they are targeted with these medications to prevent GvHD. Bortezomib works by inhibiting dendritic cells, which also play a role in the development of GvHD. Giving cyclophosphamide, bortezomib and abatacept after a donor stem cell transplant may work better in preventing GvHD when compared to standard of care.